InflaRx NV
IFRX0.895USD
+0.070+8.42%
Handelsschluss 02/06, 16:00（ET）Kurse um 15 Minuten verzögert
60.63MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über InflaRx NV Unternehmen
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Informationen
BörsenkürzelIFRX
Name des UnternehmensInflaRx NV
IPO-datumNov 08, 2017
CEORiedemann (Niels C)
Anzahl der mitarbeiter74
WertpapierartOrdinary Share
GeschäftsjahresendeNov 08
AddresseWinzerlaer Str. 2
StadtJENA
BörseNASDAQ OMX - NASDAQ BASIC
LandGermany
Postleitzahl07745
Telefon493641508180
Websitehttps://www.inflarx.de/
BörsenkürzelIFRX
IPO-datumNov 08, 2017
CEORiedemann (Niels C)
Führungskräfte von InflaRx NV
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Wed, Mar 5
Währung: USDAktualisiert: Wed, Mar 5
FY2022
FY2021
FY2020
FY2019
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
Germany
0.00
0.00%
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Andere
77.94%
Aktionäre
Aktionäre
Anteil
Suvretta Capital Management, LLC
9.57%
BofA Global Research (US)
3.65%
683 Capital Management LLC
3.32%
RA Capital Management, LP
2.91%
Guo (Renfeng M.D.)
2.60%
Andere
77.94%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
17.39%
Individual Investor
6.38%
Research Firm
5.02%
Venture Capital
2.91%
Investment Advisor
1.36%
Investment Advisor/Hedge Fund
1.05%
Bank and Trust
0.02%
Andere
65.87%
Institutionelle Beteiligung
Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
78
18.80M
27.75%
-4.64M
2025Q3
77
16.63M
24.55%
-5.58M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Sep 30, 2025
BofA Global Research (US)
2.48M
3.65%
+2.48M
--
Sep 30, 2025
683 Capital Management LLC
2.25M
3.32%
-225.00K
-9.09%
Sep 30, 2025
RA Capital Management, LP
1.97M
2.91%
--
--
Sep 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.73M
2.55%
+90.20K
+5.50%
Sep 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Ikarian Capital LLC
722.07K
1.07%
+17.06K
+2.42%
Sep 30, 2025
Morgan Stanley & Co. LLC
626.60K
0.92%
-66.75K
-9.63%
Sep 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
